Evidence map›Paper›PMID 37375794›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Sucrosomial

Susana Gómez-Ramírez, Elisa Brilli, Germano Tarantino, Domenico Girelli, Manuel Muñoz

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Rationale and design of the RISE-HF trial: sucrosomial iron in heart failure.International journal of cardiology. Heart & vasculature · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025
    Article
  16. Article
  17. Management of preoperative anemia: iron replacement.Blood transfusion = Trasfusione del sangue · 2025
    Article
  18. Comparative evaluation of different oral iron salts in the management of iron deficiency anemia.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Susana Gómez-RamírezDepartment of Internal Medicine, University Hospital "Virgen de la Victoria", 29010 Málaga, Spain.
Elisa BrilliScientific Department, Alesco S.r.l., Via delle Lenze, 56122 Pisa, Italy.
Germano TarantinoScientific Department, Pharmanutra S.p.A., Via delle Lenze, 56122 Pisa, Italy.
Domenico GirelliDepartment of Medicine, University of Verona, 37129 Verona, Italy.ORCID 0000-0001-9684-1899
Manuel MuñozPerioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain.ORCID 0000-0002-2052-8959
Hospital Clínico Universitario Virgen de la Victoria · ESUniversidad de Málaga · ESUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide. Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID). However, its use is associated with gastrointestinal side effects, thus compromising treatment compliance. Intravenous iron administration is a more costly and logistically complex alternative and is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial

Indexed as

anemiabioavailabilityefficacyintravenous ironiron deficiencyoral iron saltspatient blood managementSucrosomial® irontolerability

Identifiers

PMID37375794
PMCPMC10305423
OpenAlexW4379800428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.